Search Results for "Biomedix"
Original Source: BioMedix
BioMedix is a new biotechnology company that specializes in developing and manufacturing high quality, high performance, cutting-edge ELISA assays. At BioMedix, we are committed to providing the most comprehensive panel of high quality research and diagnostic reagents at the most reasonable prices. We offer products covering the areas of research in cytokines and chemokines, adhesion molecules, cancer research, and apoptosis.
Matching Channels
None
Matching News
Helix BioMedix second quarter revenue decreases 32% to $471,000
Helix BioMedix, Inc., a developer of bioactive peptides, today announced financial results for the second quarter ended June 30, 2012.
BioMedix® Launches Enhanced Non-Invasive Vascular Testing Devices, PADnet® and VEINnet™
ST. PAUL, Minn., Dec. 18, 2012 /PRNewswire/ -- BioMedix, a leader in healthcare IT designed to help manage disease and optimize medical practices, today introduced exciting technology for non-...
Safecode Drug Technologies Receives Investment From Biomedix Ltd
JERUSALEM, January 7, 2013 /PRNewswire/ -- - Israel's publicly-traded (TASE) BioMedix Agrees to Purchase SAFC at 0.15 cents Per Share SafeCode Drug Technologies Corp. (OTCBB: SAFC), a developer of a...
SafeCode Drug Technologies Receives Investment From Biomedix Ltd.
JERUSALEM, Jan. 6, 2013 /PRNewswire/ -- SafeCode Drug Technologies Corp. (OTCBB: SAFC), a developer of a voice recognition drug administration safety application announced today that Israeli's B...
ProGaming Platforms Corp. Executes Share Swap Agreement With BioMedix Ltd.
NEW YORK, February 18, 2013 /PRNewswire/ -- ProGaming Platforms Corp. ( OTCQB: PPTF), an Israeli-based developer of a commercial multiplayer online gaming and reward processing platform, today announ...
Suspect Detection Systems Receives Funding From Israel-Publicly Traded Biomedix Ltd.
NEW YORK, April 3, 2013 /PRNewswire/ -- Funding can support enhancing the Cogito Solution's marketing efforts, that management believe, can assist in Preventing Potential School/Mall Massacres Suspe...
Helix BioMedix Reports Third Quarter 2012 Financial Results
Helix BioMedix, Inc. (OTCQB: HXBM), a developer of bioactive peptides, today announced financial results for the third quarter ended September 30, 2012. Third Quar...
Helix BioMedix Announces Plan for Voluntary Suspension of SEC Reporting Obligations
Helix BioMedix, Inc. (OTCQB: HXBM) (the “Company”), a developer of bioactive peptides, today announced that it has filed a Schedule 13E-3 and related preliminary proxy stateme...
Matching PubMed Articles
None
